Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
KOV-HIPEC-01 trial: what clinicians have said so far
Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer
- NCT01091636 ↗
- Completed
- National Cancer Center, Korea
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on KOV-HIPEC-01 (epithelial ovarian cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KOV-HIPEC-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Randomized Trial of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer
- Phase
- Phase 2/Phase 3
- Status
- Completed
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Hyperthermic Intraperitoneal Chemotherapy
- Arms
- HIPEC · Experimental
- No HIPEC · No intervention
- Enrollment
- 184
- Primary outcomes
- Progression free survival
- Sponsor
- National Cancer Center, Korea with Ajou University
- Start
- Mar 2010
- Primary completion
- Jan 10, 2020
- Results posted
- No
- Registry record
- NCT01091636 · updated Feb 17, 2020
Publications
linked from the registry- Lim MC, Kang S, Choi J, Song YJ, Park S, Seo SS, Park SY. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol. 2009 Apr;16(4):993-1000. doi: 10.1245/s10434-008-0299-y. Epub 2009 Jan 24. PubMed 19169758
- Kim JH, Chun SY, Lee DE, Woo YH, Chang SJ, Park SY, Chang YJ, Lim MC. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01). Gynecol Oncol. 2023 Mar;170:19-24. doi: 10.1016/j.ygyno.2022.12.021. Epub 2023 Jan 4. PubMed 36608383
- Kim JH, Lee DE, Lee Y, Ha HI, Chang YJ, Chang SJ, Park SY, Lim MC. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01). J Gynecol Oncol. 2022 Jul;33(4):e54. doi: 10.3802/jgo.2022.33.e54. Epub 2022 May 31. PubMed 35712968
- Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY; HIPEC for Ovarian Cancer Collaborators. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. JAMA Surg. 2022 May 1;157(5):374-383. doi: 10.1001/jamasurg.2022.0143. PubMed 35262624